Lanadelumab is a Monoclonal antibody targeting Kallikreins, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Brexpiprazole: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.

Valsartan is a Small molecule drug targeting AT1R, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Elivaldogene Autotemcel: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.

Fesomersen is a ASO targeting F11, at Pending. This 2026 report reviews clinical evidence, IP, deals, risks and a HOLD / OPTION view.

Ranibizumab (Genentech) is a Fab fragment targeting VEGF-A, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Beremagene geperpavec is a Gene therapy targeting COL7A1, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Vixarelimab: Phase 1/2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical, IP, deals, and risks.

Zidesamtinib is a Small molecule drug targeting ROS1, at NDA/BLA. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Semorinemab is a Monoclonal antibody targeting TAU, at Discontinued. This 2026 report reviews clinical evidence, IP, deals, risks and a HOLD / OPTION view.

Betibeglogene autotemcel is a Gene therapy, Hematopoietic stem cell therapy targeting β-globin, at Approved. This 2026 report reviews clinical evidence.

Lovotibeglogene autotemcel is a Gene therapy targeting β-globin, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.